KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Jazz Pharmaceuticals (JAZZ) Equity Ratio: 2009-2025

Historic Equity Ratio for Jazz Pharmaceuticals (JAZZ) over the last 15 years, with Sep 2025 value amounting to 0.35.

  • Jazz Pharmaceuticals' Equity Ratio rose 2.43% to 0.35 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.35, marking a year-over-year increase of 2.43%. This contributed to the annual value of 0.34 for FY2024, which is 3.90% up from last year.
  • Per Jazz Pharmaceuticals' latest filing, its Equity Ratio stood at 0.35 for Q3 2025, which was up 2.94% from 0.34 recorded in Q2 2025.
  • Jazz Pharmaceuticals' 5-year Equity Ratio high stood at 0.56 for Q1 2021, and its period low was 0.26 during Q3 2022.
  • In the last 3 years, Jazz Pharmaceuticals' Equity Ratio had a median value of 0.33 in 2024 and averaged 0.33.
  • In the last 5 years, Jazz Pharmaceuticals' Equity Ratio plummeted by 45.45% in 2022 and then climbed by 17.81% in 2023.
  • Jazz Pharmaceuticals' Equity Ratio (Quarterly) stood at 0.32 in 2021, then fell by 11.67% to 0.28 in 2022, then climbed by 15.17% to 0.33 in 2023, then grew by 3.90% to 0.34 in 2024, then rose by 2.43% to 0.35 in 2025.
  • Its Equity Ratio stands at 0.35 for Q3 2025, versus 0.34 for Q2 2025 and 0.36 for Q1 2025.